Please login to the form below
lebrikizumab
This page shows the latest lebrikizumab news and features for those working in and with pharma, biotech and healthcare.
Dermira craters as acne drug fails late-stage test
Also in its pipeline is an injectable drug for atopic dermatitis - I L-13 inhibitor lebrikizumab - which was developed by Roche and licensed to Dermira in a deal valued at up ... That programme is in mid-stage clinical testing. Even if it successfully
Latest news
-
Setback for AZ as tralokinumab flunks asthma trial
The failure of tralokinumab hasn’t come out of the blue, as another trial (STRATOS 1) also failed to hit the mark, and other IL-13 inhibitors - including Roche’s lebrikizumab
-
Roche out-licenses lebrikizumab rights to Dermira
Roche out-licenses lebrikizumab rights to Dermira. Swiss drug maker stands to receive $80m upfront for the drug. ... Roche has opted to out-license the bulk of the rights to its IL-13 inhibitor lebrikizumab to dermatology company Dermira in a deal valued
-
AZ trial adds to pessimism about anti-IL-13 asthma drugs
It looks increasingly like a lost cause as AZ already reported disappointing phase IIb data with tralokinumab, and last year Roche reported disappointing results with its anti-IL-13 candidate lebrikizumab,
-
Teva gets EU nod for severe asthma drug Cinqaero
13 inhibitor lebrikizumab.
-
Roche shares slip as profits miss expectations
Aside with atezolizumab, Roche is also looking ahead to possible launches for multiple sclerosis candidate ocrelizumab - also due for filing shortly - as well as asthma drug lebrikizumab.
More from news
Approximately 2 fully matching, plus 10 partially matching documents found.
Latest Intelligence
-
Pharma deals during August 2014
This brings a much needed boost to its respiratory portfolio, which currently consists of Pulmozyme (cystic fibrosis) and Xolair (severe asthma) and products in clinical development, eg lebrikizumab (severe asthma).
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
-
Senior Programme Executive
-
Salary TBC
- Head of Operations/ BUD, Healthcare PR, London – Excellent leade...
-
Excellent Package
- Principal Medical Writer, Medical Communications, Relocate to Ca...
-
Excellent Salary
- Editorial Team Leader or Scientific Director
-
£50, 000 - £55, 000 benefits
- FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...
-
EXCELLENT DAY RATES AVAILABLE
-
Senior Medical Writer
-
Great salary and bebefits
- Senior Account Manager – Med Comms – Kent
-
Salary TBC
- Editor > Senior Editor – Medical Education – London
-
Very competitive with excellent benefits
- FREELANCE Account Manager – Creative Healthcare Advertising – Lo...
-
SUPERB DAY RATES AVAILABLE
-
Account Manager, Healthcare PR
-
£40, 000 – £42, 000 great benefits and bonuses
-
Senior Medical Writer
-
Great salary and benefits
-
Scientific Director
-
Great salary and bebefits
- Senior Account Manager / Account Director
-
Great salary and bebefits
- Senior Medical Writer, Medical Communications, Relocate to Cardi...
-
Excellent Salary
- Senior / Principal Regulatory Writer – Home Working - UK or US
-
HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS
- Account Manager – Med Comms – London
-
Salary TBC
Subscribe to our email news alerts
PMHub
CSafe Global
CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...
Latest intelligence
- Pharma’s isolated islands of innovation
- With service design and technology often failing the patient, why perspective on improving outcomes need to change...
- Uncertainty, austerity and Brexit
- What does it mean for the life science sector?...
- The Holy Grail of HCP Access
- This is the data you need to gain access....
Quick links
Infographics
